Enovis (ENOV), a global medical technology company, Friday, announced that Davide Visentin will take over as President of Enovis International Surgical, effective March 1.
Visentin succeeds Benjamin Reinmann, who has played a pivotal role in shaping the company's International Surgical Business.
Most recently, Visentin served as Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit at BD.
ENOV is currently trading at $46.70 up 2.71 percent or $1.23 on the Nasdaq.
For comments and feedback: editorial@rttnews.com